{"id":"W3213641793","doi":"10.25251/skin.5.supp.62","title":"Tapinarof Cream 1% Once Daily for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults: The Pivotal Phase 3 ADORING Clinical Program","year":2021,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Innovaderm (Canada)","funders":"LEO Pharma; EMD Serono; Bausch Health; Glenmark Pharmaceuticals; Sanofi Genzyme; Incyte; Dermira; Regeneron Pharmaceuticals; Kiniksa Pharmaceuticals; Celgene; Sanofi; Amgen; Pfizer; Galderma; Ortho Dermatologics; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Atopic dermatitis; Medicine; Dermatology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004718131,0.0001627919,0.0006389063,0.00005683877,0.000133604,0.000009583782,0.0001745943,0.0000610242,0.00003483427],"category_scores_gemma":[0.0007080311,0.00006828518,0.0001540334,0.0001645724,0.0003459115,0.00003917206,0.00002910444,0.000243171,8.280334e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003784441,"about_ca_system_score_gemma":0.0001792433,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003952355,"about_ca_topic_score_gemma":0.00005997483,"domain_scores_codex":[0.998309,0.0002453057,0.0008164642,0.0001360196,0.0002784028,0.0002147694],"domain_scores_gemma":[0.997379,0.001610334,0.0003232873,0.0003059462,0.0002330014,0.0001484363],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.01356079,0.008178055,0.1245061,0.0003128587,0.00268009,0.004753709,0.01662281,0.0005656708,0.0001423081,0.00009467689,0.01723205,0.8113508],"study_design_scores_gemma":[0.07536919,0.04388746,0.4416094,0.006945523,0.006810724,0.3727321,0.01619102,0.00681327,0.003294562,0.00161186,0.02415807,0.0005768041],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9654814,0.0168783,0.0001574156,0.01614838,0.0002161966,0.001004981,0.00001635433,0.000007377231,0.00008960252],"genre_scores_gemma":[0.990539,0.007272467,0.0002809019,0.00127269,0.0004573113,0.00002340387,0.000007568445,0.00001384679,0.0001328377],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.810774,"threshold_uncertainty_score":0.2784589,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0176862136550827,"score_gpt":0.3443466066119262,"score_spread":0.3266603929568435,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}